Key Non-Cancerous Blood Disease Market Players:
- Amgen Inc. (USA)
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Pfizer Inc. (USA)
- Takeda Pharmaceutical Co. (Japan)
- Novartis AG (Switzerland)
- Sanofi S.A. (France)
- CSL Limited (Australia)
- Johnson & Johnson (USA)
- Grifols S.A. (Spain)
- Baxter International Inc. (USA)
- Bayer AG (Germany)
- Novo Nordisk A/S (Denmark)
- Biocon Biologics Ltd. (India)
- SK Plasma Co., Ltd. (South Korea)
- Kedrion Biopharma (Italy)
- Hanmi Pharmaceutical Co. (South Korea)
- Intas Pharmaceuticals Ltd. (India)
- Pharmaniaga Bhd (Malaysia)
- Chugai Pharmaceutical Co., Ltd. (Japan)
- Aspen Pharmacare (Australia)
The global non-cancerous blood disease market is very competitive among the key players aiming with different strategies to making the market grow significantly. Amgen, Roche, Pfizer, Takeda, and Novartis are the leader due to the robust global distribution and advanced biologics. To satisfy growing demand in both established and emerging countries, businesses are concentrating more on developing gene therapies, expanding biosimilars, and developing plasma-derived medications. Further, the Roche-Chugai and Biocon-Viatris are expanding the reach and production.
The top 20 cohort of such key players include:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of non-cancerous blood disease is evaluated at USD 26.9 billion.
Non-Cancerous Blood Disease Market size was valued at USD 24.9 billion in 2024 and is set to exceed USD 47.8 billion by 2037, expanding at over 7% CAGR during the forecast period i.e., between 2025-2037.
North America is the dominant region in the market and is expected to hold the market share of 36.8% at a CAGR of 7.5% by 2034.
The major players in the market are Amgen Inc. (USA), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (USA), Takeda Pharmaceutical Co. (Japan), Novartis AG (Switzerland), Sanofi S.A. (France), CSL Limited (Australia), Johnson & Johnson (USA), Grifols S.A. (Spain), Baxter International Inc. (USA), Bayer AG (Germany), and others.
